Antibody-drug maker Raven Biotech goes public with VaxGen merger
See our story about the merger of these two South San Francisco, Calif., biotechs in Monday’s daily briefing at VentureBeat Life Sciences.
Next Story: Life sciences briefing: Tuesday, Nov. 13, 2007
Previous Story: Chemokine-drug maker ChemoCentryx files for $58M IPO
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.